Discovering Satb2: A Potential Drug Target and Biomarker (G23314)

Target Name: SATB2

NCBI ID: G23314

SATB2

Discovering Satb2: A Potential Drug Target and Biomarker

SATB2, also known as SATB2 homeobox 2, is a gene that encodes a protein known as Satb2. Satb2 is a non-coding RNA molecule that plays a role in the development and maintenance of tissues in the body.

The SATB2 gene was first identified in 2011 by researchers using transcriptomics techniques. The gene is located on chromosome 6, and it encodes a protein that is expressed in a variety of tissues throughout the body.

One of the unique features of Satb2 is its ability to self-regulate. This means that the gene can be controlled by the body's own internal systems, such as the immune system and the development of cancer. This self-regulation is critical for the development and maintenance of tissues, and it is a potential drug target.

Satb2 is also known for its role in the development and maintenance of tissues in the brain. Studies have shown that Satb2 is expressed in the brain and that it is involved in the formation and maintenance of neural stem cells. This suggests that Satb2 may be a potential drug target for a variety of neurological disorders, including Alzheimer's disease and Parkinson's disease.

In addition to its role in the brain, Satb2 is also involved in the development and maintenance of tissues in the heart, lungs, and other organs. This suggests that Satb2 may be a potential drug target for a variety of diseases that affect these tissues, including cancer, heart disease, and respiratory disorders.

The discovery of Satb2 as a potential drug target is the result of a collaboration between researchers from the University of California, San Diego and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The researchers identified Satb2 as a potential drug target using a variety of techniques, including transcriptomics, RNA sequencing, and biochemical assays.

In addition to its potential drug-targeting properties, Satb2 also has potential as a biomarker. The researchers have used Satb2 to measure the expression of the gene in a variety of tissues and have shown that the gene is expressed in a consistent pattern across different tissues . This suggests that Satb2 could be used as a biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and respiratory disorders.

The discovery of Satb2 as a potential drug target and biomarker is the result of a significant investment in research and development by the National Institutes of Health (NIH). The NIDDK is a part of the National Institutes of Health and is responsible for supporting and funding research in the prevention, diagnosis, and treatment of diabetes and other chronic diseases.

In conclusion, Satb2 is a gene that encodes a protein that is expressed in a variety of tissues throughout the body and has potential as a drug target and biomarker. The discovery of Satb2 by researchers from the University of California, San Diego and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a significant step forward in the development of new treatments for a variety of diseases. Further research is needed to fully understand the potential of Satb2 as a drug target and biomarker.

Protein Name: SATB Homeobox 2

Functions: Binds to DNA, at nuclear matrix- or scaffold-associated regions. Thought to recognize the sugar-phosphate structure of double-stranded DNA. Transcription factor controlling nuclear gene expression, by binding to matrix attachment regions (MARs) of DNA and inducing a local chromatin-loop remodeling. Acts as a docking site for several chromatin remodeling enzymes and also by recruiting corepressors (HDACs) or coactivators (HATs) directly to promoters and enhancers. Required for the initiation of the upper-layer neurons (UL1) specific genetic program and for the inactivation of deep-layer neurons (DL) and UL2 specific genes, probably by modulating BCL11B expression. Repressor of Ctip2 and regulatory determinant of corticocortical connections in the developing cerebral cortex. May play an important role in palate formation. Acts as a molecular node in a transcriptional network regulating skeletal development and osteoblast differentiation

The "SATB2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SATB2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets